[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cogent Biosciences Inc (COGT)

Cogent Biosciences Inc (COGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,961,610
  • Shares Outstanding, K 162,309
  • Annual Sales, $ 0 K
  • Annual Income, $ -328,940 K
  • EBIT $ -333 M
  • EBITDA $ -332 M
  • 60-Month Beta 0.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.63

Options Overview Details

View History
  • Implied Volatility 59.77% (-7.80%)
  • Historical Volatility 51.31%
  • IV Percentile 1%
  • IV Rank 0.91%
  • IV High 370.26% on 07/03/25
  • IV Low 56.91% on 01/21/26
  • Expected Move (DTE 23) 3.80 (10.32%)
  • Put/Call Vol Ratio 1.67
  • Today's Volume 211
  • Volume Avg (30-Day) 940
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 23,808
  • Open Int (30-Day) 23,605
  • Expected Range 33.02 to 40.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.53
  • Number of Estimates 7
  • High Estimate $-0.34
  • Low Estimate $-0.66
  • Prior Year $-0.52
  • Growth Rate Est. (year over year) -1.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.79 +8.35%
on 03/23/26
39.41 -7.10%
on 03/31/26
+3.23 (+9.68%)
since 03/20/26
3-Month
32.70 +11.96%
on 03/20/26
40.45 -9.49%
on 02/25/26
-2.92 (-7.39%)
since 01/22/26
52-Week
4.30 +750.41%
on 04/25/25
43.73 -16.28%
on 12/08/25
+32.27 (+743.55%)
since 04/22/25

Most Recent Stories

More News
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., April 21, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

COGT : 36.31 (-1.14%)
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors ...

COGT : 36.31 (-1.14%)
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GIST Bezuclastinib...

COGT : 36.31 (-1.14%)
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

WALTHAM, Mass. and BOULDER, Colo., March 16, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

COGT : 36.31 (-1.14%)
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms 99% of patients achieve >50% reduction in serum tryptase...

COGT : 36.31 (-1.14%)
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for bezuclastinib...

COGT : 36.31 (-1.14%)
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

COGT : 36.31 (-1.14%)
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

-   Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan....

COGT : 36.31 (-1.14%)
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) 

-  PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR...

COGT : 36.31 (-1.14%)
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to...

COGT : 36.31 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cogent Biosciences Inc. is a biotechnology company. It is focused on developing precision therapies for genetically defined diseases. The company's program consist PLX9486. Cogent Biosciences Inc., formerly known as Unum Therapeutics Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 38.32
2nd Resistance Point 37.86
1st Resistance Point 37.29
Last Price 36.31
1st Support Level 36.26
2nd Support Level 35.80
3rd Support Level 35.23

See More

52-Week High 43.73
Last Price 36.31
Fibonacci 61.8% 28.67
Fibonacci 50% 24.02
Fibonacci 38.2% 19.37
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.